Abstract: The present invention concerns a biomaterial comprising a nanofibrous scaffold made of polymers, such as poly(?-caprolactone) or collagen, coated with at least one layer pair consisting of a layer of polyanions and a layer of polycations, wherein said at least one layer pair incorporates a therapeutic molecule such as a growth factor. The biomaterial may optionally comprise living cells such as osteoblasts and/or chondrocytes.
Type:
Grant
Filed:
February 22, 2012
Date of Patent:
July 31, 2018
Assignee:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Inventors:
Nadia Benkirane-Jessel, Didier Mainard, Carlos Mendoza Palomares
Abstract: The present invention relates to a method for predicting the outcome of a cancer. More particularly, the present invention relates to a method for predicting the outcome of a cancer in a patient comprising a step consisting of determining the expression level of a miRNA cluster in a sample obtained from said patient, wherein said miRNA cluster comprises: -miR.609 or, -miR.518c or, -miR.520f or, -miR.220a or, -miR.362 or, -miR.29a or, -miR.660 or, -miR.603 or, -miR.558 or, -miR519b or, -miR.494 or, -miR.130a or, -miR.639.
Type:
Application
Filed:
January 12, 2018
Publication date:
July 26, 2018
Applicants:
Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITÉ PARIS DESCARTES, ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS (APHP)
Inventors:
Jérôme GALON, Bernhard MLECNIK, Franck PAGES, Hervé FRIDMAN
Abstract: Disclosed is a method for processing asynchronous signals generated by a light sensor, the sensor having a matrix of pixels, the method including: —receiving the asynchronous signals, each signal being associated with a pixel in a group of pixels in the matrix, each signal including successive events issued by the associated pixel; —upon an occurrence of an event in one of the asynchronous signals, updating an integration value associated to the group by adding an additive value to the integration value; —if the integration value is greater than a predetermined threshold, generating an event in an outputted asynchronous signal.
Type:
Application
Filed:
July 18, 2016
Publication date:
July 26, 2018
Applicants:
UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventors:
Ryad BENOSMAN, Francesco GALLUPI, Guillaume CHENEGROS, Xavier LAGORCE, Christoph POSCH
Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
Type:
Grant
Filed:
June 30, 2017
Date of Patent:
July 24, 2018
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Curie, Universite Paul Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)
Abstract: In order to obtain a predetermined ultrasonic wave field in a homogeneous internal part of a medium masked by an aberrating barrier, an ultrasonic lens is interposed between the emitting ultrasonic probe and the aberrating barrier. The ultrasonic lens is calculated by using a model of the medium comprising a mapping of ultrasonic wave propagation properties obtained from actual imaging of the medium such that when the ultrasound probe sends a predetermined ultrasonic wave, said predetermined wave generates the predetermined objective ultrasonic wave field in the medium.
Type:
Application
Filed:
June 30, 2016
Publication date:
July 12, 2018
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
Inventors:
Mickaël Tanter, Jean-François Aubry, Thomas Deffieux, Mathieu Pernot
Abstract: The present invention provides a method for the diagnosis of disorders caused by foetal alcohol syndrome, said method comprising the assaying of PLGF (placental growth factor).
Type:
Application
Filed:
June 22, 2016
Publication date:
July 12, 2018
Applicants:
Centre Hospitalier Universitaire De Rouen, Universite De Rouen Normandie, Institut National De La Sante Et De La Recherche Medicale (INSERM)
Inventors:
Bruno José Gonzalez, Stéphane Marret, Matthieu Jean Alexandre Lecuyer, Annie Laquerriere, Soumeya Bekri, Céline Lesueur, Sylvie Marguerite Alberte Jegou, Pascale Yvonne Joséphine Marcorelles
Abstract: The present invention relates to a compound which is an antagonist of the GluK2/GluK5 receptor or an inhibitor of the GluK2/GluK5 receptor expression for use in the treatment or the prevention of epilepsy.
Type:
Grant
Filed:
September 16, 2014
Date of Patent:
July 10, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE BORDEAUX
Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
Type:
Grant
Filed:
November 4, 2014
Date of Patent:
July 10, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.
Type:
Grant
Filed:
August 8, 2014
Date of Patent:
July 10, 2018
Assignees:
INSTITUTE PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT-PARIS 7, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
Inventors:
Marie-Lise Gougeon, Manuelle Viguier, Hervé Bachelez, Nicolas Fazilleau
Abstract: The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.
Type:
Grant
Filed:
March 16, 2016
Date of Patent:
July 10, 2018
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU), UNIVERSITE DE LILLE 2 DROIT ET SANTE
Inventors:
Nicolas Sergeant, Luc Buee, Patricia Melnyk, Marion Gay, Nicolas Le Fur
Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.
Type:
Grant
Filed:
April 24, 2015
Date of Patent:
July 3, 2018
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE D'AUVERGNE, UNIVERSITE DE MONTPELLIER
Inventors:
Philippe Brabet, David Cia, Laurent Guillou, Christian Hamel, Claire Vigor, Thierry Durand, Céline Crauste, Joseph Vercauteren
Abstract: The present invention relates to the biological production of methane (Biogas) by co-culture in an aerobic atmosphere of a methanogenic bacterium and of an anaerobic bacterium capable of producing hydrogen, in a culture medium comprising or being supplemented with carbohydrate compound(s), notably starch and/or sugars, and supplemented with antioxidant compound(s).
Type:
Grant
Filed:
April 20, 2015
Date of Patent:
July 3, 2018
Assignees:
FONDATION MEDITERRANEE INFECTION, UNIVERSITE D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventors:
Didier Raoult, Saber Khelaifia, Michel Drancourt
Abstract: The invention relates to a method for generating ultrasonic waves focused on a focal zone (5) in order to carry out biological lesions, comprising the activation of a plurality of ultrasonic transducer elements (3). According to the invention: a target zone, in which homogenization of the supply of energy of the ultrasonic waves emitted by the ultrasonic transducer elements is desired, is chosen, the focusing effect and the acoustic attenuations of the ultrasonic waves on their path between the target zone and the ultrasonic transducer elements (3) are determined, the focusing effect and the acoustic attenuations of the ultrasonic waves are compensated, with ultrasonic transducer elements (3) at least some of which have non-identical emission surfaces such that in the target zone, the supply of energy of the ultrasonic waves emitted by the different ultrasonic transducer elements (3) is more or less identical.
Type:
Application
Filed:
February 21, 2018
Publication date:
June 28, 2018
Applicants:
EDAP TMS FRANCE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
Inventors:
Jérémy VINCENOT, David MELODELIMA, Emmanuel BLANC, Jean-Yves CHAPELON
Abstract: The present invention relates to an in vitro use of a number of IL-4 and/or IL-13 secreting T-cells as a biomarker for diagnosing and/or monitoring an IgE-dependent allergic disease.
Type:
Grant
Filed:
July 22, 2014
Date of Patent:
June 26, 2018
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PIERRE ET MARIE CURIE—PARIS 6
Abstract: Antagonist of the BTLA/HVEM interaction for use in therapy The present invention relates to an antagonist of the BTLA/HVEM interaction for use in therapy, wherein said antagonist increases the proliferation of V?9V?2 T cells.
Type:
Grant
Filed:
February 21, 2014
Date of Patent:
June 26, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
Inventors:
Daniel Olive, Christine Pasero, Julie Gertner-Dardenne
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of age-related macular degeneration (AMD). In particular the present invention relates to RdCVFL polypeptide or polynucleotide for use in the treatment of AMD.
Type:
Grant
Filed:
October 17, 2013
Date of Patent:
June 26, 2018
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Abstract: The method determines parameters to generate confocal ultrasound beams (B1,B2) inside a medium (4), and uses a device (1) comprising first and second ultrasound means (11,12) and first and second displacement members (13,14) for moving the ultrasound means (11,12). The parameters include signals s1,s2 to the ultrasound means (11,12), and the positions x1,x2 of the ultrasound means (11,12). The parameters are optimized for having a minimum amplitude a1,a2 of the signals s1,s2 and having an acoustic effect inside the medium (4).
Type:
Grant
Filed:
March 8, 2013
Date of Patent:
June 26, 2018
Assignees:
INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE CLAUDE BERNARD, CENTRE LÉON BÉRARD
Abstract: The present Inventors demonstrated that the RelB subunit of NF?B plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the NF?B pathway through RelB phosphorylation at serine 472. In a first aspect, the present invention proposes to monitor the activation of the NF?B pathway by following the phosphorylation status of said serine. Also, the present invention discloses methods and kits for prognosing the evolution of a disease involving cell migration in a subject—treated or not—suffering thereof, based on the detection of said RelB-S472 phosphorylation.
Type:
Application
Filed:
November 20, 2017
Publication date:
June 7, 2018
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS ), UNIVERSITE PARIS DESCARTES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M EDICALE (INSERM)